CytoDyn (CYDY) Deferred Taxes (2018 - 2019)
CytoDyn (CYDY) posted Deferred Taxes of $26919.0 for Q2 2019, down 99.05% on a QoQ basis from $2.8 million in Q4 2018.
CytoDyn (CYDY) Deferred Taxes (2018 - 2019) Analysis & Trends
CytoDyn's Deferred Taxes history runs 2 years deep, the most recent figure standing at $26919.0 for Q2 2019.
- Quarterly Deferred Taxes changed N/A year-over-year to $26919.0 in Q2 2019, while the trailing twelve-month figure through May 2020 was $26919.0 (down 99.06% YoY) and the FY2019 annual result came in at -$2.8 million, changed N/A from the prior year.
- Deferred Taxes was $26919.0 for Q2 2019 at CytoDyn, down from $2.8 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $2.8 million in Q4 2018 and bottomed at $26919.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytoDyn | 267.79 Mn | 267.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2019 | 26,919.00 |
| Nov 30, 2018 | 2.83 Mn |